RxDoctor Payments DataLook up a doctor →

Erich Garland, MD

Neurology · Idaho Falls, IDNPI 1689664724

Payments from drug & device makers

$33,342in general payments, 2019–2025

Across 970 payments — averaging $34.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acorda Therapeutics, Inc$13K
  • Medtronic$2K
  • AbbVie$2K
  • EMD Serono, Inc.$2K
  • Sanofi$2K
  • Bristol Myers Squibb$2K
  • plus $11K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Acorda Therapeutics, Inc21$12,511
Medtronic6$2,095
AbbVie(2 entities)140$2,022
EMD Serono, Inc.101$1,905
Sanofi31$1,871
Bristol Myers Squibb106$1,522
Biogen67$1,349
Teva Pharmaceuticals USA, Inc.34$887
UCB, Inc.39$832
Amgen(2 entities)18$771
SK Life Science, Inc.33$691
Acadia Pharmaceuticals Inc38$623
Vanda Pharmaceuticals Inc.20$508
Supernus Pharmaceuticals, Inc.37$488
AstraZeneca20$405
Sunovion Pharmaceuticals Inc.29$400
Novartis24$364
TG Therapeutics, Inc.18$364
E.r. Squibb & Sons, L.L.C.11$337
Argenx US, Inc.16$305
Neurocrine Biosciences, Inc.14$251
Lilly USA, LLC12$203
Jazz Pharmaceuticals Inc.9$175
Banner Life Sciences, LLC7$152
Neurelis, Inc.9$151
Livanova USA, Inc.9$143
Eisai Inc.8$136
CSL Behring6$132
Genentech USA, Inc.7$127
Biohaven Pharmaceutical Holding Company Ltd.5$126
Greenwich Biosciences, Inc.8$125
Lundbeck LLC6$122
Xeris Pharmaceuticals, Inc.5$97
Pfizer5$95
Otsuka America Pharmaceutical, Inc.1$92
Catalyst Pharmaceuticals, Inc.4$81
Boston Scientific5$72
Takeda Pharmaceuticals U.S.A., Inc.2$69
Ardelyx, Inc.3$67
Abbott3$50
Biohaven Pharmaceuticals, Inc.3$44
Adamas Pharmaceuticals, Inc.2$43
Grifols USA, LLC2$41
Cala Health, Inc.2$39
Alnylam Pharmaceuticals Inc.2$38
Upsher-smith Laboratories LLC2$38
GE HealthCare1$30
Arbor Pharmaceuticals, Inc.2$28
Johnson & Johnson2$28
Stryker1$27
Axsome Therapeutics, Inc.1$26
Avanir Pharmaceuticals, Inc.1$25
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$24
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$23
Tanabe Pharma America, Inc.1$21
Amneal Pharmaceuticals LLC1$20
Ipsen Biopharmaceuticals, Inc1$20
Merck1$18
Cycle Pharmaceuticals Inc1$18
Aimmune Therapeutics, Inc.1$17

How this compares

$33,342 in reported general payments places this provider in the 85th percentile of 59 neurology providers in Idaho.

See all neurology providers in Idaho

Medicare billing

Part B allowed, 2024
$31,091
Medicare patients
209
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Idaho Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →